GlassScriptPhysician profile
Sarah E Scolpini
NPI 1417739665
$1,623.32
in general payments reported to CMS, 2019-2025
23 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.58 · 2024: $1,356 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $310.10 | 2024 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $255.26 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $182.93 | 2023-2025 | Evenity, Prolia, Tepezza |
| Kyowa Kirin, INC. | $90.43 | 2024-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $83.68 | 2024-2025 | |
| Astellas Pharma US INC | $80.24 | 2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.38 | 2024 | Jardiance |
| Novo Nordisk INC | $64.61 | 2024-2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $61.39 | 2024 | Xyosted |
| Abbvie INC. | $48.33 | 2024 | |
| Acella Pharmaceuticals, LLC | $44.11 | 2024 | NP Thyroid 60 |
| Insulet Corporation | $43.01 | 2024 | Omnipod |
| Medtronic, INC. | $40.29 | 2024-2025 | Minimed 780g |
| Dexcom, INC. | $38.22 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $31.01 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $28.56 | 2024 | |
| Alexion Pharmaceuticals, INC. | $28.30 | 2024 | Strensiq |
| Sequel Med Tech, LLC | $26.21 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $24.59 | 2024 | |
| Neurocrine Biosciences, INC. | $21.38 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.68 | 2024 | |
| Beta Bionics, INC. | $17.24 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $14.37 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Scolpini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.